on brain magnetic resonance imaging (MRI), magnetic resonance angiography (MRA), and magnetic resonance venography (MRV), and no ipsilateral internal carotid artery plaque, atrial fibrillation, or cardiac thrombus. 9 All 11 patients had at least 1 heritable thrombophilic-hypofibrinolytic coagulation disorder. We speculated that AF can be caused by reversible (by anticoagulation) retinal artery thrombi associated with heritable thrombophilia or hypofibrinolysis, or both, often augmented by estrogen-driven acquired thrombophilia. 9 Although AF is transient but often recurrent, 2,4,5,8-10 it foretells a high subsequent complication rate, including 1% annual blindness rate, 2% annual risk of an ischemic insult, and rates of 30% for myocardial infarction and 18% for mortality. Hence, a thorough search for treatable underlying etiologies is important, commonly involving carotid and vertebral duplex imaging, MRI, MRA, MRV, Amaurosis fugax (AF) is most commonly caused by emboli from ipsilateral, atherosclerotic, carotid artery plaque and less commonly by atrial fibrillation, cardiac thrombi, vasospasm, giant cell arteritis, systemic lupus erythematosus, or anticardiolipin antibodies. [1] [2] [3] [4] [5] [6] [7] [8] We recently studied thrombophilia and hypofibrinolysis in 11 white patients (8 women, 3 men, 57 ± 17 years) with AF who were selected by the absence of abnormal results Summary: Nineteen patients (age 60 ± 14) with amaurosis fugax associated with heritable thrombophiliahypofibrinolysis without ipsilateral atherosclerotic carotid plaque or other causes of amaurosis fugax were studied. Our hypothesis was that case-specific thromboprophylaxis would prevent subsequent amaurosis fugax episodes. Prospective treatment data were available for 13 cases. Thrombophilic disorders included high Factors VIII and XI, G20210A prothrombin heterozygosity, low proteins C and S, MTHFR mutations, and the PL A1/A2 mutation. Hypofibrinolytic disorders included plasminogen activator inhibitor-1 4G4G, and high lipoprotein (a). Treatments included Coumadin; Lovenox, folic acid-vitamin B6-vitamin B12, discontinuation of estrogens-selective estrogen receptor modulators, Glucophage, and aspirin, as appropriate. Usually within 1 month on therapy, patients became asymptomatic and have remained asymptomatic for ≥ 1 year on therapy, without adverse treatment side effects. When amaurosis fugax occurs without carotid artery atherosclerosis or other known causes, thrombophilia or hypofibrinolysis, or both are nearly universal, safely treatable, reversible pathoetiologies.
and ophthalmologic, neurologic, serologic (antiphospholipid antibodies), and cardiac evaluation, including electrocardiogram and echocardiography.
Beyond carotid artery surgery, medical therapy has included fibrinolysis, 11 anticoagulants, [12] [13] [14] and antiplatelet agents. 12, 14, 15 As in the current report, antiplatelet agents lack efficacy in the presence of heritable thrombophilias, 9, 13, 16 which include G1691A factor V Leiden, high factor VIII, [17] [18] [19] [20] familial protein S deficiency, C677T methylenetetrahydrofolate reductase (MTHFR) homozygosity, and C677T-A1298C MTHFR compound heterozygosity. 21 Instead, therapy must be based on low-molecular-weight heparin (short-term), Coumadin (long-term; Bristol-Myers Squibb, New York, NY), and folic acid, vitamin B6, and vitamin B12 for MTHFR-homocysteine disorders. 21 The association of inherited thrombophilias with AF is not surprising because thrombophilias cause retinal artery thrombosis 16 and nonarteritic ischemic optic neuropathy. 22, 23 We speculated that thromboprophylaxis in patients with AF associated with heritable thrombophilia-hypofibrinolysis may help to prevent the otherwise high risk of later development of AF and reduce the risk for retinal artery thrombosis, transient cerebral ischemic attacks, or ischemic strokes, [11] [12] [13] [14] [15] 24 for which AF is a predictive forerunner. 1, 2, 4, 5, 8 
PATIENTS AND METHODS

Study Design
The study was conducted following a protocol approved by the Jewish Hospital Institutional Review Board, with signed informed consent. To enter the study, patients had to have been diagnosed by ophthalmologists as having AF with transient monocular loss of vision. 5 Patients were selected by the absence of abnormal results of brain MRI, MRA, MRV, absence of atrial fibrillation, or cardiac thrombus (by echocardiography), and were required to have carotid and vertebral duplex imaging examinations that were negative for ipsilateral, hemodynamically significant atherosclerotic plaque. The MRI, MRV, MRA, and carotid and vertebral duplex imaging studies were completed in the Alliance Hospitals' Vascular Laboratories and Diagnostic Imaging divisions. Electrocardiograms and echocardiography were done in the Alliance Hospitals' cardiology division.
Patients
The 19 patients who met the exclusion criteria were referred to the outpatient Cholesterol Center from 3 ophthalmology practices and were prospectively enrolled in the study in the temporal order of their referral, without known selection bias. None had previous studies of thrombophilia-hypofibrinolysis. They had all experienced 2 or more episodes of transient monocular vision loss 5 (usually less than 10 minutes' duration). The initial visit to the Cholesterol Center, 21 or more days after the ocular vascular event, included a detailed history and physical examination. The medical history was reviewed for connective tissue disease, lupus erythematosus, hypertension, cigarette smoking, estrogen use, diabetes, pulmonary embolus, deep venous thrombosis, repetitive pregnancy loss, and antiphospholipid antibody syndrome, and therapy for hypertension, type II diabetes mellitus, and hyperlipidemia. No patients had taken Coumadin or heparin within 3 months of blood sampling.
Plasma Preparation
Blood was collected in 3.2% buffered sodium citrate. 25, 26 The samples were immediately centrifuged at 2600g for 15 minutes to obtain plateletpoor plasma. Blood for polymerase chain reaction (PCR) analysis was drawn in ethylenediaminetetraacetic acid tubes and the DNA was extracted for subsequent analysis.
Coagulation Assays
Polymerase chain reaction assays were done as previously described 9 for 5 gene mutations: G1691A Leiden mutation in the factor V gene, G20210A mutation of the prothrombin gene, C677T and A1298C mutations of the MTHFR gene, 4G/5G polymorphism of the PAI-1 gene promoter, and the platelet glycoprotein IIb/IIIa (PL A1/A2, thymine to cytosine substitution at position 196).
Non-PCR coagulation tests in plasma and serum were done by following previously published methods. 9 The tests done in plasma were dilute Russell's viper venom time, activated partial thromboplastin time, resistance to activated protein C, factors VIII and XI, plasminogen activator inhibitor activity (PAI-Fx), protein C antigenic, protein S total (antigenic), protein S free (antigenic), and antithrombin III (functional). The tests done in serum were anticardiolipin antibodies, homocysteine, and lipoprotein (a) (Lp [a]).
RESULTS
All 19 patients were found to have at least 1 heritable thrombophilic-hypofibrinolytic disorder ( Table 1) . The most common coagulation disorders were MTHFR C677T homozygosity or C677T-A1298C compound heterozygosity in 7, PAI-1 4G4G homozygosity in 6, high factor VIII in 5, resistance to activated protein C in 5, the platelet glycoprotein PL A1/A2 mutation in 4, high Lp(a) in 3, low free protein S in 2, and high PAI-Fx in 2. There were single patients with G 1691A V Leiden heterozygosity, G20210A prothrombin gene heterozygosity, and protein C deficiency, low antithrombin III, high anticardiolipin antibody immunoglobulin G, and high factor XI.
Four patients (Nos. 1 to 4, Table 1 ) took Coumadin for 16, 16, 22 , and 98 months. One patient had high factor VIII (207%), 1 was a G20210A prothrombin gene heterozygote with high factor XI (188%) and resistance to activated protein C, 1 had protein C deficiency (41%), and 1 had free protein S deficiency (53%) with high factor VIII (157%), resistance to activated protein C, and PAI-1 4G4G homozygosity. Amaurosis fugax resolved in these patients, usually within 1 month of starting Coumadin, and the patients remained asymptomatic provided that the INR remained at 2.5 or above. With monthly monitoring of the INR, there have been no significant bleeding events in these 4 patients and no changes in hematocrit or hemoglobin.
One patient (No. 5, Table 1 ) had low free protein S (28%) and MTHFR homozygosity. She was treated for 8 months of pregnancy and 1 month postpartum with Lovenox (80 mg/d; Sanofi-Aventis, Paris France) and folic acid (5 mg), vitamin B6 (100 mg), and vitamin B12 (2000 µg/d). Amaurosis fugax disappeared within 1 week, and she remained asymptomatic. No bleeding events occurred during the pregnancy or in the first postpartum month, and the complete blood count did not change during therapy.
In 3 patients with MTHFR C677T homozygosity or C677T/A1298C compound heterozygosity (Nos. 6 to 8, Table 1 ) treated with folic acid (5 mg), vitamin B6 (100 mg), and vitamin B12 (2000 µg/d) for 10, 15, and 29 months, AF resolved, usually within 1 month of starting therapy, and has not recurred. No side effects were associated with the folic acid and vitamins B6 and B12 therapy.
In 2 patients (No. 9 with PAI-1 4G4G, PL A1/A2 and No. 10, Table 1 , with high factor VIII [160%], C677T/A1298C compound MTHFR homozygosity, high Lp(a) [82 mg/dL], and resistance to activated protein C), when exogenous estrogensselective estrogen receptor modulators (SERMs) were discontinued, AF disappeared within 1 month and has not recurred.
The frequency of AF events was reduced in 2 patients (Nos. 11 and 12, Table 1 ) taking 81 mg aspirin alone (1 high factor VIII [156%], 1 PL A1/A2), during 5 and 11 months. No side effects were associated with the aspirin use.
In 1 patient with hypofibrinolysis (4G4G PAI-1 polymorphism, high PAI Fx [31.7 IU/mL]) and PL A1/A2 heterozygosity (No. 13, Table 1 ) treated for 12 months with Glucophage (2.55 g/d; Bristol-Myers Squibb) and aspirin (81 mg), symptoms resolved within 1 month and have not recurred. No side effects resulted from the Glucophageaspirin throughout.
DISCUSSION
Long-term anticoagulation prevents recurrence of symptoms of AF in patients with antiphospholipid antibody syndrome. 7 Previously, there have been no systematic studies of patients whose AF was not associated with the usual causes: emboli from ipsilateral, atherosclerotic, carotid artery plaque, and less commonly by atrial fibrillation, cardiac thrombi, vasospasm, giant cell arteritis, systemic lupus erythematosus, or anticardiolipin antibodies. [1] [2] [3] [4] [5] [6] [7] [8] However, as we have recently reported in 11 patients with AF, without ipsilateral atherosclerotic carotid artery placque, 9 heritable thrombophiliahypofibrinolysis alone can often cause AF, presumably via transient (and reversible) retinal artery thrombosis.
In the current study, in 4 patients with heritable thrombophilia taking Coumadin (without bleeding events) for 16, 16, 22 , and 98 months, AF resolved, usually within 1 month of starting Coumadin. The patients remained asymptomatic provided that the INR remained at 2.5 or greater. In 1 patient with low free protein S treated for 8 months of pregnancy and 1 month postpartum on Lovenox (80 mg/d), AF disappeared within 1 week, and she remained asymptomatic. There were no bleeding events or changes in the complete blood count during Lovenox therapy.
In 3 patients with MTHFR C677T homozygosity or C677T/A1298C compound heterozygosity, treated with folic acid and vitamins B6 and B12 for 10, 15, and 29 months, AF resolved, usually within 1 month of starting therapy, and has not recurred. No side effects were associated with the B vitamin therapy.
In 2 patients with thrombophilia-hypofibrinolysis, when exogenous estrogens-SERMs were discontinued, AF disappeared and has not recurred. This probably represents the synergistic superposition 
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of exogenous estrogen-induced thrombophilia on heritable thrombophilia-hypofibrinolysis. 23 The frequency of AF events was reduced by aspirin alone in 2 patients with heritable thrombophilia, and AF events have remained less frequent over 5 and 11 months with aspirin therapy.
In 1 patient with heritable hypofibrinolysis with high PAI-Fx treated with Glucophage (2.55 g/d) and aspirin (81 mg), without side effects, symptoms resolved within 1 month, and have not recurred in 12 months with the Glucophage-aspirin treatment. By lowering serum insulin and insulin resistance, Glucophage reduces insulin-inducible, hypofibrinolytic PAI-Fx. 27 In future studies of AF where thrombophiliahypofibrinolysis are the only risk factors, and in the absence of ipsilateral carotid atherosclerosis, a blinded, placebo-control, randomized trial of thromboprophylaxis would be needed to optimally document significant alteration of the natural history of AF. The results from the current study and previous studies, 9, 13 indicate that when AF occurs in the absence of carotid artery atherosclerosis, thrombophilia and/or hypofibrinolysis 9,13 are nearly universal, safely treatable, and reversible pathoetiologies.
